Kedrion Achieves Orphan Drug Designation from EMA
This designation marks a significant milestone for patients and reaffirms Kedrion's commitment to addressing unmet medical needs in rare and ultra-rare diseases.
Understanding Congenital Aceruloplasminemia
Kedrion has announced that the European Medicines Agency (EMA) has officially granted Orphan Drug Designation (ODD) to its investigational treatment for Congenital Aceruloplasminemia (ACP), a rare genetic disorder affecting iron metabolism. Aceruloplasminemia is caused by mutations in the CP gene, leading to a lack of Ceruloplasmin, a vital plasma protein essential for iron transport. In the absence of treatment, dangerous amounts of iron may accumulate in the brain, liver, and pancreas, leading to severe neurological symptoms, diabetes, anemia, and retinal degeneration.
Kedrion's Commitment to Innovation
The EMA's decision emphasizes Kedrion's dedication to being a science-driven innovator within the rare and ultra-rare disease arena. By leading the development of therapies derived from unused plasma fractionation intermediates, Kedrion transforms industrial plasma waste into promising new treatments. This innovative strategy not only maximizes the use of valuable resources but also promotes sustainability within the biopharmaceutical industry.
A Strong Message from Leadership
Andrea Caricasole, Chief R&D and Innovation Officer at Kedrion, expressed, "This designation from EMA, alongside the recent ODD granted by the FDA, reaffirms our science-focused approach to addressing rare diseases. By unlocking the therapeutic potential of Ceruloplasmin, we aim to provide options for patients suffering from Aceruloplasminemia, a devastating condition with currently no effective treatments available. This milestone is a concrete step toward making a new therapy accessible to these patients. We believe our research aligns with sustainable practices that create meaningful solutions for serious health challenges."
Collaboration and Support
This achievement is the outcome of a collaborative effort involving academic and clinical partners and has received support from the Italian Ministry for Enterprises and Made in Italy (MIMIT) through the research initiative named "NATURAL." The project aims to enhance research on new therapies by utilizing unused plasma fractionation intermediates.
Recent Scientific Publications
Kedrion's approach is further showcased by two recent impactful scientific publications. One study in Nature Communications Biology demonstrated the potential for purifying Ceruloplasmin and its therapeutic efficacy in preclinical ACP models. The Lancet eBioMedicine provided important insights into the prevalence of the condition using real-world data, strengthening the case for developing targeted therapies for this ultra-rare disorder.
Looking Forward: Advancing Treatment Development
Kedrion is committed to advancing its treatment for Aceruloplasminemia through clinical development in Europe, aiming to facilitate timely access for patients without effective treatment options.
About Kedrion Biopharma
Kedrion Biopharma specializes in collecting and fractionating blood plasma to create and distribute plasma-derived therapies that address rare, ultra-rare, and serious conditions such as coagulation disorders, neurological disorders, and immunodeficiencies. The company employs approximately 5,200 individuals worldwide, with comprehensive industrial networks comprising plasma collection facilities in multiple countries and production centers across five countries. Kedrion is dedicated to fostering innovation and improving care through collaboration with the medical-scientific community, institutions, and patient advocacy groups, ensuring that every connection made resonates positively in the lives of patients globally.
Frequently Asked Questions
What is Orphan Drug Designation?
Orphan Drug Designation is a status granted by regulatory authorities to encourage the development of treatments for rare diseases, offering various incentives to developers.
What is Congenital Aceruloplasminemia?
Congenital Aceruloplasminemia is a rare genetic disorder caused by a mutation affecting iron metabolism, leading to serious health complications.
What are the implications of the EMA's decision?
The EMA's Orphan Drug Designation for Kedrion's treatment signifies recognition of the drug’s potential to address urgent medical needs for patients with Aceruloplasminemia.
How will Kedrion's treatment help patients?
Kedrion's treatment aims to provide therapeutic options for untreated patients, potentially alleviating the severe symptoms associated with Aceruloplasminemia.
What role does collaboration play in drug development?
Collaboration between Kedrion and academic, clinical partners, along with governmental support, enhances the research and development process, leading to innovative solutions for patients.
